Ultimovacs ASA - Share Option Program
Oslo, 21April 2022: On the basis of the approval by the General Meeting on 21 April 2022 to authorize the Board of Directors of Ultimovacs ASA (the ‘Company’, OSE ticker “ULTI”) to issue new shares to employees under a long-term incentive program, the Board of Directors has resolved to issue share options to employees in the Company.
A total of 480,000 options for shares in the Company have been distributed amongst the employees. The number of options granted corresponds to 1.40% of the outstanding number of shares in the Company. Each option gives the right to acquire one share in the Company. The options are granted without consideration.
Pursuant to the vesting schedule, 25% of the options will vest one year after the day of grant, 25% of the options will vest two years after the day of grant and the remaining 50% will vest three years after the day of grant (vesting is dependent on the option holder still being employed in the Company).
The exercise price for the options granted is NOK 83.46 per share.
Options that are not exercised within 7 years from the date of grant will lapse and become void. The option life of all previously granted options in 2019, 2020 and 2021 has also been extended from 5 to 7 years.
No primary insiders in Ultimovacs, being board members and the CEO, received any option grant in 2022.
For further information, please see www.ultimovacs.com or contact:
Jónas Einarsson, Chair of the Board of Directors of Ultimovacs ASA
Phone: +47 480 96 355
Carlos de Sousa, CEO
Phone: +47 908 92507
Anne Worsøe, Head of IR & Communication
Phone: +47 906 86815
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Notification and Public Disclosure of Transactions by Person Discharging Managerial Responsibilities24.5.2022 11:00:00 CEST | Press release
Company Announcement No. 38/2022 Copenhagen, 24 May 2022 Notification and Public Disclosure of Transactions by Person Discharging Managerial Responsibilities 1. Information on the person discharging managerial responsibilities/person closely associated a) Name Anders Obel 2. Reason for the notification a) Position/title Member of the Board of Directors b) Initial notification/amendment Initial notification 3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name Scandinavian Tobacco Group A/S b) LEI code 5299003KG4JS99TRML67 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of the financial instrument, type of instrument Identification code Shares DK0060696300 – STG b) Nature of the transaction Sale of shares c) Price(s) and volume(s) Price(s)Volume(s)DKK 147.6 7,
Disclosure of voting rights for Chairman of the Board24.5.2022 10:44:47 CEST | Press release
Oslo, 24 May 2022. PCI Biotech Holding ASA ("PCI Biotech" or the "Company") issue this notification on behalf of its chairman, Hans Peter Bøhn. Hans Peter Bøhn is chairman of PCI Biotech and shall open the annual general meeting of the Company on 25 May 2022. Mr. Bøhn holds 123,662 shares, representing 0.3 per cent of the share capital of PCI Biotech. Mr. Bøhn has received powers of attorney to represent and vote for 7,234,249 additional shares. In total, Mr. Bøhn will represent and vote for 19.7 per cent of the share capital. A major part of the powers of attorney are without voting instructions. The powers of attorney are only valid at the annual general meeting on 25 May 2022. This information is subject to the disclosure requirements pursuant to section 4 -3, cf. section 5-12 of the Norwegian Securities Trading Act. Contact information: PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo Ronny Skuggedal, CFO, firstname.lastname@example.org, Mobile: +47 9400 5757
PRESS RELEASE: NQX has been certified by NCSA-FI for security level TL III24.5.2022 10:15:00 CEST | Press release
NQX has been certified by NCSA-FI for security level TL III SSH announced today that it has received a TL III-level security certification for its NQX quantum line encryption software version 2.2 from the Finnish National Cyber Security Center (NCSA). The certification enables the solution to be used to secure networks requiring TL III level encryption for the transmission of confidential and sensitive information. The certified NQX 2.2 includes central management functionality that enables convenient remote management of network nodes. NQX central manager simplifies and automates the management and maintenance of Public Key Infrastructures (PKI) and certifications of nodes and connections regardless of their location. Because of its intuitive user interface, NQX central manager is easy to use and administrators can perform critical management tasks with minimal human effort. NQX's capability to support various network deployment approaches is enhanced with an isolated management chann
RESULT OF RIKSBANK CERTIFICATE SALE24.5.2022 10:15:00 CEST | Press release
AuctionAuction resultsAuction date2022-05-24Start date2022-05-25Maturity date2022-06-01Interest rate, %0.25Offered volume, SEK bn603.0Total bid amount, SEK bn2818.6Accepted volume, SEK bn603.0Number of bids18Percentage allotted, %21.394
Selligent Marketing Cloud Boosts Customer Engagement with New Smart Subject Capabilities24.5.2022 10:00:00 CEST | Press release
AI Drives Next-Generation Subject Line Optimization for Marketers, Saving Time and Increasing Performance BRUSSELS, Belgium and NASHVILLE, Tenn., May 24, 2022 (GLOBE NEWSWIRE) -- Selligent Marketing Cloud (Selligent), the intelligent omnichannel marketing automation platform and CM Group brand, today announced the launch of Smart Subject, an AI-based individual subject line optimization capability that improves campaign performance and reduces the manual labor of subject line creation for marketers. Smart Subject, along with a series of other new AI-capability offerings, is built to help brands stand out in a crowded inbox, enhancing personalized marketing across languages. With Smart Subject, marketers can send the optimal subject line for every contact in their segment through the use of: Automatic Subject Line Matching: Selligent’s Natural Language Processing-based engine will find the optimal subject line for every contact.Instant Feedback: Smart Subject can identify what percentag